Area of building.

No definition available.

Name:	celu_AreaOfBuilding
Namespace Prefix:	celu_
Data Type:	dtr-types:areaItemType
Balance Type:	na
Period Type:	duration

- Definition

Closing bid price of common stock consecutive business days

+ References

No definition available.

+ Details

Name:	celu_ClosingBidPriceOfCommonStockConsecutiveBusinessDays
Namespace Prefix:	celu_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Closing bid price per share of common stock.

+ References

No definition available.

+ Details

Name:	celu_ClosingBidPricePerShareOfCommonStock
Namespace Prefix:	celu_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Debt instrument payment.

+ References

No definition available.

+ Details

Name:	celu_DebtInstrumentPayment
Namespace Prefix:	celu_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Debt instrument payment partial payment.

+ References

No definition available.

+ Details

Name:	celu_DebtInstrumentPaymentPartialPayment
Namespace Prefix:	celu_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Debt Instrument Payment Remaining Balance

+ References

No definition available.

+ Details

Name:	celu_DebtInstrumentPaymentRemainingBalance
Namespace Prefix:	celu_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Debt instrument remaining amount repayment.

+ References

No definition available.

+ Details

Name:	celu_DebtInstrumentRemainingAmountRepayment
Namespace Prefix:	celu_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Description of Organization and Business Operations (Details) [Line Items]

+ References

No definition available.

+ Details

Name:	celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems
Namespace Prefix:	celu_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Minimum bid price requirement compliance period.

+ References

No definition available.

+ Details

Name:	celu_MinimumBidPriceRequirementCompliancePeriod
Namespace Prefix:	celu_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of clinical trials.

+ References

No definition available.

+ Details

Name:	celu_NumberOfClinicalTrials
Namespace Prefix:	celu_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of premium principal amount.

+ References

No definition available.

+ Details

Name:	celu_PercentageOfPremiumPrincipalAmount
Namespace Prefix:	celu_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Unrestricted cash and cash equivalents.

+ References

No definition available.

+ Details

Name:	celu_UnrestrictedCashAndCashEquivalents
Namespace Prefix:	celu_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Date when an entity was incorporated

+ References

No definition available.

+ Details

Name:	dei_EntityIncorporationDateOfIncorporation
Namespace Prefix:	dei_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of the required periodic payments including both interest and principal payments.

+ References

+ Details

Name:	us-gaap_DebtInstrumentPeriodicPayment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

+ Details

Name:	us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

+ Details

Name:	us-gaap_NetCashProvidedByUsedInOperatingActivities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	na
Period Type:	duration

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

+ Details

Name:	us-gaap_OperatingIncomeLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).

+ References

No definition available.

+ Details

Name:	us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

+ Details

Name:	us-gaap_RetainedEarningsAccumulatedDeficit
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name:	us-gaap_SharePrice
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16)(a)(1))
-URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(13))
-URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878

+ Details

Name:	us-gaap_ShortTermBorrowings
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=celu_CellTherapyClinicalTrialUpdateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CreditFacilityAxis=celu_PrePaidAdvanceAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LineOfCreditFacilityAxis=celu_YorkvilleMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Nature of Business - Additional Information (Details)										1 Months Ended	3 Months Ended
Nature of Business - Additional Information (Details)	Jun. 14, 2023 USD ($)	May 16, 2023 USD ($)	May 14, 2023 USD ($)	Apr. 14, 2023 USD ($)	Apr. 10, 2023 USD ($)	Mar. 24, 2023 USD ($)	Mar. 14, 2023 Days $ / shares	Feb. 22, 2023 USD ($)	Feb. 21, 2023 USD ($)	Apr. 30, 2023 USD ($) $ / shares	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($) ft² ClinicalTrial	Mar. 31, 2022 USD ($)	May 22, 2023 USD ($)	Dec. 31, 2022 USD ($)
Description Of Organization And Business Operations Details [Line Items]
Date of incorporation												Aug. 24, 2018
Percentage of reduction in workforce												0.33%
Number of clinical trials \| ClinicalTrial												2
Area of building \| ft²												147,215
Net operating loss												$ (63,870,000)	$ (41,614,000)
Net cash used in operating activities												(14,995,000)	(34,253,000)
Accumulated deficit												709,513,000			$ 645,496,000
Debt principal balance												30,945,000			$ 37,603,000
Unrestricted cash and cash equivalents												5,700,000
Impairment charge												0	$ 0
Forecast \| IPR&D Asset \| Cell Therapy Clinical Trial Update
Description Of Organization And Business Operations Details [Line Items]
Impairment charge											$ 89,100,000
Subsequent Event
Description Of Organization And Business Operations Details [Line Items]
Debt instrument payment					$ 5,500,000
Class A Common Stock
Description Of Organization And Business Operations Details [Line Items]
Closing Bid Price per Share of Common Stock \| $ / shares							$ 1.00
Consecutive business days \| Days							30
Minimum bid price requirement compliance period							180 days
Pre-Paid Advance Agreement \| Yorkville
Description Of Organization And Business Operations Details [Line Items]
Debt principal balance												$ 32,400,000
Amount of monthly repayment								$ 6,000,000	$ 6,500,000
Debt instrument payment						$ 1,950,000
Percentage of premium principal amount								5.00%	5.00%			5.00%
Pre-Paid Advance Agreement \| Yorkville \| Forecast
Description Of Organization And Business Operations Details [Line Items]
Debt instrument payment	$ 6,600,000
Pre-Paid Advance Agreement \| Yorkville \| Subsequent Event
Description Of Organization And Business Operations Details [Line Items]
Debt principal balance														$ 21,800,000
Debt instrument payment		$ 5,600,000
Debt Instrument Payment Remaining Balance			$ 6,500,000	$ 4,600,000	5,500,000
Share price per share \| $ / shares										$ 0.50
Debt Instrument Payment Partial Payment					$ 900,000					$ 900,000
Debt instrument remaining amount repayment			$ 5,600,000